🇺🇸 FDA
Patent

US 11672762

Onapristone extended-release compositions and methods

granted A61KA61K31/575A61K9/20

Quick answer

US patent 11672762 (Onapristone extended-release compositions and methods) held by CONTEXT BIOPHARMA, INC. expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CONTEXT BIOPHARMA, INC.
Grant date
Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/575, A61K9/20, A61K9/2054, A61P